RxDoctor Payments Data

Imran Dosani, MD

Nephrology · Lawrenceville, GANPI 1215142401

Payments from drug & device makers

$634in general payments, 2019–2025

Across 16 payments — averaging $39.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$206
  • AstraZeneca$137
  • Otsuka America Pharmaceutical, Inc.$119
  • Fresenius USA Marketing, Inc.$41
  • Lundbeck LLC$40
  • Amgen$34
  • plus $57 from 2 others

What the payments were for

  • Speaking & faculty fees$20032%
  • Food & beverage$30248%
  • Education$13221%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$634 in reported general payments places this provider in the 30th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$300,877
Medicare patients
554
Services billed
2,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan25$497,075
XphozahTenapanor Hcl16$85,851
KerendiaFinerenone85$58,543
AuryxiaFerric Citrate32$47,025
VeltassaPatiromer Calcium Sorbitex13$25,189
LokelmaSodium Zirconium Cyclosilicate34$24,161
InvokanaCanagliflozin30$22,956
EntrestoSacubitril/Valsartan15$19,402
Sevelamer Carbonate156$17,881
FarxigaDapagliflozin Propanediol24$17,721
Lanthanum Carbonate14$17,317
Cinacalcet Hcl57$14,459
JardianceEmpagliflozin15$12,843
SpsSodium Polystyrene Sulfon/Sorb21$4,332
Calcium Acetate39$3,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$119$497,07525 claims
BayerKerendia$32$58,54385 claims
Akebia Therapeutics IncAuryxia$25$47,02532 claims
AstraZenecaLokelma, Farxiga$137$41,88158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 388 nephrology providers in Georgia.

Other nephrology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →